natgillin/translations-raw huggingface dataset:
The 18th item relates to a floor panel according to the 17th item, characterized in that the strip is snap-fitted in place in the recess (13). 
Podni panel sukladno zahtjevu 17, naznačen time što je traka na način da se zatvara škljocanjem pričvršćena u otvor (13).
In particular, this result is obtained by means of appropriate calibrated holes obtained in correspondence with each user device. 
Taj rezultat se dobiva naročito pomoću odgovarajuće kalibracije otvora koji se prave tako da odgovaraju svakom korisniku uređaja.
Aspect 17. An aqueous composition according to aspect 15-16, wherein the reactive compound is selected from the group consisting of formaldehyde, ethanol, chlorophorm, trichloroethylene, acetone, triton-X-100, deoxycholate, diethylpyrocarbonate, sulphite, Na2S2O5, beta-proprio-lacton, polysorbate such as Tween 20®, Tween 80®, O2, phenol, pluronic type copolymers, and a combination of any thereof. 
Vodeni pripravak sukladno zahtjevima 1 do 9, koja dalje sadrži reaktivni spoj odabran iz skupine sastavljenu od formaldehida, etanola, kloroforma, trihloroetilena, acetona, polietilen glikol terc-oktilfenil etera, deoksikolata, dietilpirokarbonata, sulfita, Na,S205, beta-proprio-laktona, polisorbata, opciono Polisorbata 20 ili Polisorbata 80, O,, fenola, kopolimera pluronskog tipa, i bilo koje njihove kombinacije.
The heating program was set to heat the sample at a heating rate of 10 °C/min to a temperature of approximately 250 °C. 
Program zagrijavanja je postavljen da zagrije uzorak brzinom od 10%C /min do temperature od približno 250%C.
A further aspect of the present invention is a kit of parts comprising a dosage unit of a first active ingredient, which is a sulphonylpyrrole derivative mentioned in above or a salt thereof, a dosage unit of a second active ingredient, which is an art-known standard therapeutic, in particular an anti-cancer agent such as e.g. one of those mentioned above, and optionally instructions for simultaneous, sequential or separate use in therapy, e.g. to treat disorders responsive or sensitive to the inhibition of histone deacetylases, such as, for example, benign or malignant neoplasia, e.g. cancer. 
Kombinacija, naznačena time što sadrži prvi aktivni sastojak, koji je najmanje jedna sol spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 9,1 drugi aktivni sastojak, koji je najmanje jedno sredstvo protiv raka, kojeg se bira iz skupine koju čine kemoterapijska sredstva protiv raka i ciljno specifična sredstva protiv raka, namijenjen odvojenoj, uzastopnoj, istodobnoj, paralelnoj ili kronološki razdijeljenoj upotrebi u terapiji, primjerice u terapiji dobroćudnih ili zloćudnih novotvorina, primjerice raka.
The compression mixture was compressed to obtain tablets. 
Kompresijska smjesa je komprimirana, čime su dobivene tablete.
The pharmaceutical composition according to claim 2 or 3, wherein the pharmaceutical composition is in sustained-release tablet form containing Pirfenidone, active in the reduction and/or regression of the deleterious effects in breast capsular contracture observed after the surgical implantation of breast implants in humans. 
Farmaceutski pripravak prema bilo kojem od zahtjeva 1 ili 2, naznačen time da je za uporabu za liječenje štetnih učinaka kod kapsularne kontrakture dojke. Farmaceutski pripravak prema zahtjevu 4, naznačen time da je za uporabu za liječenje štetnih učinaka kod kapsularne kontrakture dojke primijećene nakon kirurške implantacije implantata za grudi kod ljudi.
The process according to claim 4 wherein said enzyme catalyst is selected from the group consisting of NIT-101, NIT-102, NIT-103 and nitrilase from Arabidopsis thaliana. 
Postupak u skladu s patentnim zahtjevom 4, gdje navedeni enzimski katalizator se bira iz skupine koju čine NIT101, NIT-102, NIT-103 initrilaza iz biljke Arabidopsis thaliana. t>&
A compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein both of R1 and R2 are ethyl. 
Spoj u skladu sa zahtjevom 2 ili njegova farmaceutski prihvatljiva sol, naznačen time, da oba dva R1 i R2 su etil.
Reaction mixture is concentrated under vacuum, water (15 mL) is added to the residue and extracted with dichloromethane (3x20 mL). 
Reakcijsku smjesu koncentrira se u vakuumu, ostatku se doda voda (15 ml), te ekstrahira diklormetanom (3 x 20 ml).
SEC analysis at M3 or T2 or T4 of: monomer content greater than about 90%; aggregates content of less than about 3 wt %; and fragment 3 content less than about 5 wt %: and 
SEC analizom u T> sa: sadržajem monomera većim od 90%; sadržajem agregata od manje od 3 tež%; 1 sadržajem fragmenta 3 manjim od 5 tež%.
The ether extracts were combined, dried over MgSO4, and the solvent removed by rotary evaporation under vacuum. 
Ekstrakti etera su kombinirani, osušeni preko MgSOy, a otapalo je odstranjeno rotacionim isparavanjem pod vakuumom.
reacting a compound represented by the formula (II): 
(1) reakciju spoja prikazanog formulom (II):
The immunogenic composition of claim 1, further comprising Haemophilus influenza (H. influenzae) b capsular saccharide conjugated to a carrier protein, the carrier protein selected from the group consisting of tetanus toxoid, diphtheria toxoid, cross reactive material 197, fragment C of tetanus toxoid and protein D, wherein the H. influenzae b conjugate is present in a lower dose than the dose of any other bacterial saccharide conjugate. 
Postupak u skladu s patentnim zahtjevima 1-8, naznačen time što proteinski nosač sadrži jedan ili više epitopa iz pomoćničkih T-stanica. Postupak u skladu s patentnim zahtjevima 1-9, naznačen time što se proteinski nosač bira iz skupine koju čine: TT, DT, CRM197, fragment C od TT, protein D iz bakterije H. influenzae, pneumokokni PhtD, te pneumokokni pneumolizin.
The use according to any one of claims 12 or 13, wherein the surface-treated calcium carbonate comprises ground calcium carbonate and/or precipitated calcium carbonate and/or surface-modified calcium carbonate, preferably surface-modified calcium carbonate or ground calcium carbonate. 
Uporaba prema bilo kojem od zahtjeva 10 ili 11, naznačena time da površinski obrađeni kalcijev karbonat sadrži prirodni kalcijev karbonat i/ili istaloženi kalcijev karbonat i/ili površinski modificirani kalcijev karbonat, poželjno površinski modificirani kalcijev karbonat ili prirodni kalcijev karbonat.
pH meter (Metrohm or equivalent); Conductometer (Metrohm or equivalent); 
- < pH metar (Metrohm ili njegov ekvivalent); Konduktometar (Metrohm ili njegov ekvivalent);
R—X—Y—ONO2 (I) wherein R is the prostaglandin residue of formula (II): 
Gi) naznačen time da R jest prostaglandinski ostatak formule (II):
It has also been proposed to cleave waste-PET into the components terephthalic acid and ethylene glycol. 
Također je predloženo da se otpadni PET cijepa na komponente, tereftaličnu kiselinu 1 etilen glikol.
isolating the compound of the Formula X by: 
(m) izoliranja spoja sa formulom X pomoću:
A method of decoding image, the method comprising: 
Postupak dekodiranja slike koji obuhvaća:
The crystalline form of claim 5, wherein the crystalline form is characterized by a Raman spectrum comprising at least three peaks at positions selected from the group consisting of: 664, 1162, 1458, 1614, and 1647 cm−1±4 cm−1. 
Kristalni oblik iz bilo kojeg od zahtjeva 1. - 5., pri čemu je kristalni oblik naznačen time da Ramanov spektar sadrži najmanje tri vrha u položajima odabranim iz skupine koja se sastoji od: 664, 1162, 1458, 1614 i 1647 cm"! +4 cm.
The method according to any one of claims 1-4, wherein the fatty acid or derivative thereof has a carbon chain length of not more than 22 carbon atoms. 
Postupak prema bilo kojem zahtjevu 1-4, naznačen time, da masna kiselina ili njezin derivat ima ugljikov lanac duljine od najviše 22 ugljikova atoma.
An organophosphate, carbamate, pyrethroid or pyrethrin as claimed in any one of claims 1 to 7 wherein exposure to the sea lice treatment agents is for a period of 10 to 100 minutes, and the first and second sea lice treatment agents are staggered by an intervening period of 15 minutes to 4 hours. 
Organofosfat, karbamat, piretroid ili piretrin prema bilo kojem od zahtjeva 1 do 7 pri čemu izlaganje sredstvima protiv morskih uši traje u razdoblju od 10 do 100 minuta, i prvo 1 drugo sredstvo protiv morskih uši su vremenski raspoređeni u razmacima od 15 minuta do 4 sata.
A compound of formula I or formula II: wherein: 
[image] ili ima formulu Ii:
Use according to any one of the preceding claims, characterized in that said 2-((1-methylpropyl)amino)ethanol is added prior to, during or after, and preferably after, a step of grinding said calcium carbonate-comprising material in said suspension. 
15.Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da je navedeni 2-((1- metilpropil)aminojetanol dodan prije, za vrijeme ili nakon, poželjno nakon koraka mrvljenja navedenog materijala koji sadrži kalcijev karbonat u navedenu suspenziju.
Packaged module for multitude of rolls (1a, 1b, 1c, 1d, 2a, 2b, 2c, 2d) or packages of panels (22a, 22b, 22c, 22d, 22e, 22f, 22g, 22h) of mineral wool, especially fibreglass insulating material, comprising: 
Pakirani modul za veći broj valjaka (Ta, Ib, Ic, Id, 2a, 2b, 2c, 2d) ili paketa ploča (22, 22b, 220, 22d, 22e, 22f, 22g, 22h) mineralne vune, osobito izolacijskog materijala od staklene vune, koji sadrži:
A combination according to claim 1 comprising 2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol or a salt, solvate, tautomer or N-oxide thereof, at least 75%, or at least 80%, or at least 85%, or at least 9 0%, or at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or at least 99.9% of which is in the S-enantiomeric form. 
Pripravak koji sadrži 2-amino-1-(4-klorlo-fenil)-1-[4-(1H-pirazol-4-il)-fenil]-etanol ili neku njegovu sol, solvat, tautomer ili N-oksid, od kojih je najmanje 90% u obliku S-enantiomera. Pripravak prema zahtjevu 1 naznačen time da je najmanje 98% u obliku S-enantiomera. Pripravak prema zahtjevu 1 naznačen time da je najmanje 99% u obliku S-enantiomera.
The blank of claim 11, wherein the outside front wall (8) of the box and/or the additional side walls (16) feature a cut-out (20) in the extrusion ridge (17). 
Shema prema zahtjevu 10 i 11, naznačena time, da prednji zid (8) kutije i/ili bočni zidovi (16) imaju otvor (20) na udubljenom rubu (17).
The formulated IL-2 bulk solution was filter sterilised into a sterile bulk tank. 
Formulirana IL-2 glavna otopina je filterski sterilizirana u sterilnom glavnom tanku.
The compound of any one of clauses (1)-(3) wherein at least one of E1a and E1b is -N(H)C(=O)OMe; 
Spoj iz bilo kojeg od patentnih zahtjeva 1-3 gdje najmanje jedno od E'* i E"" je -N(H)C(=0)0Me.
The method of clause 13, wherein said condition is female sexual dysfunction. The method of clause 18, further comprising administering a compound or compounds selected from a group consisting of estradiol, estriol, estradiol esters, progesterone and progestins to a patient in need thereof. 
Spoj ili pripravak za uporabu u postupku prema zahtjevu 9, gdje je stanje seksualna disfunkcija u žena i postupak dalje obuhvaća primjenu spoja ili spojeva izabranih iz grupe koja obuhvaća estradiol, estriol, estere estradiola, progesteron i progestine bolesniku kojemu je to potrebno.
The synthetic intermediate (E) according to claim 29, wherein R1 represents an iodine atom, a bromine atom, an ethynyl group, or a vinyl group; 
Sintezni međuprodukt (E) u skladu s patentnim zahtjevom 29, naznačen time što R1 predstavlja atom joda, atom broma, etinilnu skupinu ili vinilnu skupinu;
one coated tablet comprising 81 mg acetylsalicylic acid, two coated tablets each comprising 20 mg simvastatin and one coated tablet comprising 8 mg perindopril erbumine; 
jedna obložena tableta koja sadrži 81 mg acetilsalicilatne kiseline, dvije obložene tablete od kojih svaka sadrži 20 mg simvastatina i jedna obložena tableta koja sadrži 8 mg perindopril erbumina;
The package according to claim 1, wherein the vial is filled with cells in lyophilized form or in liquid suspension and the bag is filled with a culture medium. 
Pakiranje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time, da je bočica napunjena stanicama u liofiliziranom obliku ili u tekućoj suspenziji ili u bilo kojem drugom obliku prema vrsti stanica 1 postupku konzerviranja, a vrećica je napunjena podlogom.
The organic solution was then washed with brine and dried over sodium sulfate before evaporating to dryness. 
Organska otopina je tada bila isprana slanom vodom i osušena na natrijevom sulfatu prije uparavanja do suhoće.
Use according to claim 4 wherein said eye condition is ocular pain. 
Primjena u skladu sa patentnim zahtjevom 4 gdje spomenuto stanje oka je okularna bol.
The method of any of Paragraphs 82-90; wherein the effective amount of the compound is a twice daily dose of 50 milligrams. 
Spoj za uporabu prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen time što je učinkovita količina dnevna doza od 100 miligrama.
The coating material as recited in claim 2, wherein, the inorganic filler is selected from a precipitated calcium carbonate, a barite, blanc fixe, talcum, pyrophyllite, a chlorite, hornblende and mica, and 
Obložni materijal prema zahtjevu 6, naznačen time, da su punila odabrana iz skupine koju čine nataloženi kalcijev karbonat, barit, blank Gks, talk, pirofiltt, klorit, hornbjende i liskun.
Apparatus for treating water at low cost, according to claim 8, wherein the receiving means is covered with a material comprising membranes, geo-membranes, geotextile membranes, plastic liners, concrete, or coated concrete, or a combination thereof. 
Postupak za obradu vode uz nizak trošak, prema bilo kojem od zahtjeva 1 do 8, naznačen time što se korak dekloriranja provodi ako se otkrije rezidualni klor, te korak dekloriranja sadrži filter s aktivnim ugljenom ili kemikalije koje sadrže natrijev bisulfit, natrijev metabisulfit, ili njihovu kombinaciju.
Accessory according to one or more of the previous claims, comprising a side appendix (17A, 17B) configured and arranged so as to adhere to the back of the hand and to surround the wrist (PL) at least partially. 
Pribor u skladu s jednim ili više prethodnih patentnih zahtjeva, naznačen time, da sadržava bočni dodatak (17A, 17B) koji je oblikovan i postavljen tako da se lijepi za stražnju stranu ruke i okružuje zapešće (PL) barem djelomično.
A compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the group consisting of 
Spoj prema patentnom zahtjevu 2 ili njegova farmaceutski prihvatljiva sol, pri čemu je R; izabran iz grupe koja se sastoji od
E is an oxygen atom or an -NR8 group wherein R8 is a hydrogen atom, or a straight-chain or branched alkyl group having 1 to 5 carbon atoms; or a pharmaceutically acceptable salt thereof. 
E je atom kisika ili -NR* skupina pri čemu R* je atom vodika, ili ravnolančana ili razgranata alkil skupina koja sadrži 1 do 5 ugljikovih atoma; ili njegova farmaceutski prihvatljiva sol.
In cases when angiotensin II receptor 1 (AT-1) antagonist is administered by parenteral route, said angiotensin II receptor 1 (AT-1) antagonist, preferably telmisartan is administered in a dosage of about 0.01 to about 4 mg/kg of body weight. 
HR P20130696 T1 PATENTNI ZAHTJEVI Antagonist receptora 1 (AT-1) angiotenzina Il, naznačen time, da se upotrebljava u terapeutski djelotvornoj količini za liječenje kroničnih bolesti bubrega kod mačaka, pri čemu takav antagonist receptora 1 (AT-1) angiotenzina II je sartan.
A process according to claims 1-9 wherein the active principles are selected from herbicides, acaricides, insecticides, fungicides, biocides, plant and insect growth regulators, antidotes. 
Postupak prema zahtjevima 1-8 naznačen time da su aktivni sastojci odabrani od herbicida, akaricida, insekticida, fungicida, biocida, regulatora rasta biljaka i insekata, antidota.
Embodiments of this invention are provided with a formulation contained in vials, preferably tubing vials. 
Varijante ovog izuma osigurane su oblikom sadržanim u ampulama, poželjno ampulama pod tlakom.
The drug delivery device of Claim 16 in which the thermoset polyurethane is comprised of multifunctional polyols, multifunctional isocyanates, chain extenders or mixtures thereof. 
Uređaj za oslobađanje lijeka prema patentnom zahtjevu 16, naznačen time što se termoreaktivni poliuretan sastoji od multifunkcionalnih poliola, multifunkcionalnih izocijanata, produživača lanaca ili njihovih smjesa.
Balance (Mettler Toledo or equivalent). Materials 
- > Vaga (Mettler Toledo ili njegov ekvivalent).
The amount of the salt of N-(8-(2-hydroxybenzoyl) amino)caprylic acid in the composition may be at least 0.6 mmol, such as selected from the group consisting of at least 0.65 mmol, at least 0.7 mmol, at least 0.75 mmol, at least 0.8 mmol, at least 0.8 mmol, at least 0.9 mmol, at least 0.95 mmol and at least 1 mmol. 
Kompozicija prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što je količina navedene soli N- (8-(2-hidroksibenzoil)amino)kaprilne kiseline najmanje 0.6 mmol, kao što je izabrana iz grupe koja se sastoji od najmanje 0.65 mmol, najmanje 0.7 mmol, najmanje 0.75 mmol, najmanje 0.8 mmol, najmanje 0.8 mmol, najmanje 0.9 mmol, najmanje 0.95 mmol i najmanje 1 mmol.
wherein said part is an immunogenic fragment comprising at least 6 consecutive amino acids of the tumor-associated antigen, said tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of: 
Farmaceutski pripravak za primjenu u postupku liječenja, koja se sastoji od antitijela koje se veže za ekstracelularni dio antigena povezanog s tumorom, Navedeni s tumorom povezani antigen koji ima sekvencu koju kodira nukleinska kiselina koja se odabire iz skupine sastavljene od:
A tablet comprising apixaban and a pharmaceutically acceptable diluent or carrier, wherein the tablet is obtainable by a process comprising the steps of: 
Proces proizvodnje tableta apiksabana, pri čemu svaka tableta ima kompoziciju koja sadrži do 5 mg čestica kristalnog apiksabana i farmaceutski prihvatljiv razrjeđivač ili nosač, koji obuhvaća korake:
In the literature interleukin-6 has been proposed to act both as pro- and anti-inflammatory cytokine (reviewed in Heinrich et al., 1998, Jones et al. 2001 and Pedersen et al. 2001). 
U literaturi je predloženo da interleukin-6 djeluje i kao pro- i kao antiupalni citokin (pregledano u Heinrich i sur., 1998, Jones 1 sur. 2001 1 Pedersen i sur., 2001).
A composition for protecting an animal from an invertebrate parasitic pest comprising a parasiticidally effective amount of the polymorph Form B of claim 1 and at least one carrier. 
Smjesa za zaštitu životinje od invertebratskih parazitskih štetočina, naznačena time, što sadrži paraziticidno efikasnu količinu polimorfa iz Zahtjeva 1 i najmanje jedan nosač.
The binder preferably also contains additives. These include non-hydraulically active substances, for example, ground limestone/dolomite, precipitated CaCO3, Mg(OH)2, Ca(OH)2, silica fume, etc., and they can be metered in an amount ranging from 0.01 to 20% by weight, preferably 0.5 to 15% by weight and even more preferably of 1 to 10% by weight. 
Vezivno sredstvo sukladno barem jednom zahtjevu 1 do 4, naznačeno time štovezivno sredstvo nadalje sadrži dodatne hidraulički rektivne materijale, poput cementa kalcij aluminata, geopolimernog cementa, cementa kalcijevog sulfoaluminata i/ili nehidraulički reaktivnih materijala, poput mljevenog vapna, istaloženog CaCO;, Ca(OH),, Mg(OH),, silikatnih para i njihovih kombinacija, opsega od 1 do 30% težine, poželjno od 5 do 20% težine.
independently hydrogen or an organic residue selected from the group consisting of substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, hydroxy, lower alkoxy, carboxy or alkoxycarbonyl; or one of Rc and Rd is selected from hydrogen, substituted or unsubstituted lower alkyl and hydroxy, while the other one of Rc and Rd is a 3-7 member cyclic moiety, wherein the cyclic moiety is unsubstituted or substituted, by at least one functional group suitable for conjugation of a polymeric moiety, or 
(a) nezavisno vodik ili organski ostatak izabran iz grupe koju čine supstituirani ili nesupstituirani niži alkil, supstituirani ili nesupstituirani niži alkenil, supstituirani ili nesupstituirani niži alkinil, hidroksi, niži alkoksi, karboksi ili alkoksikarbonil; ili jedan od R" i R" je izabran od vodika, supstituiranog ili nesupstituiranog nižeg alkila i hidroksi, dok, drugi od R"i R" je 3-7 -člana ciklična grupa, pri čemu je ciklična grupa nesupstituirana ili supstituirana, sa najmanje jednom funkcionalnom grupom pogodnom za konjugaciju polimerne grupe, ili
A compound according to claim 43 wherein R15 is hydrogen or C1-C3 alkyl and Y is a covalent bond. 
Spoj u skladu s patentnim zahtjevom 43, naznačen time što R> je vodik ili Cy-C, alkil, a Y je kovalentna veza.
The aqueous solution was washed with n-hexane (50 ml) then 0.88 ammonia solution was added to give a precipitate. 
Vodena otopina ispari se s n-heksanom (50 ml) i tada se doda 0,88 otopina amonijaka da se dobije talog.
The protein peak eluted by the low pH wash, which supposedly contains mainly immunoglobulins, did not contain any r-hIL-18BP (monitored by ELISA). 
Proteinski peak eluiran ispiranjem kod niskog pH, koji bi trebao sadržavati uglavnom imunoglobuline, nije sadržavao niti malo r-hIL-18BP (praćeno ELISA testom).
is fused to another peptide or polypeptide sequence such as a linker, an activating molecule or a toxin; or is coupled to an effector molecule which mediates a therapeutic effect, such as an immune effector molecule, a toxin or a radioisotope. 
(i) fuzionirano s drugim peptidnim ili polipeptidnim slijedom, poput spojnice, aktivirajuće molekule ili toksina; ili (ii) konjugirano s efektorskom molekulom koja provodi terapijski učinak, poput imunosne efektorske molekule, toksina ili radioizotopa.
The composition of clause 15 wherein said B-cyclodextrin is hydroxypropyl B-cyclodextrin, or sulfobutylether B-cyclodextrin. The composition of clause 15 wherein said pharmaceutically acceptable salt is a hydrochloride salt, methanesulfonate, toluenesulfonate, acetate, succinate, citrate, maleate, tartrate, or mixtures thereof. 
Sastav prema zahtjevu 11, naznačeno time da je spomenuta farmaceutski prihvatljiva sol hidrokloridna sol, metan sulfonat, toluensulfonat, acetat, sukcinat, citrat, maleat, tartrat, ili mješavina istih, poželjno sol acetata.
Methotrexate has also been used in the treatment of rheumatoid arthritis, although the mechanism of action in this instance is not fully understood. 
Metotreksat je također upotrijebljen u tretiranju reumatoidnog artritisa, iako mehanizam u ovom slučaju nije potpuno razjašnjen.
The donor beads were suspended in a lysis buffer (the stimulation buffer with 0,3% Tween 20 and biotinylated cAMP) according to manufacturers instruction (Alpha screen, Perkin Elmer (Pachard Biosciense)). 
Donor zrnce se suspendira u puferu koji ima karakteristike lize (stimulacijski pufer sa 0.3 % Tween 20 i biotiniliranoj cAMP) prema uputama proizvođača (Alpha screen, Perkin Elmer (Pachard Biosciense)).
More preferably, said residue comprises three or four hydroxyl groups. 
Poželjnije, spomenuti ostatak sadržava tri ili četiri hidroksilne skupine.
iv) reacting a compound of formula (VI) with 1,2-dibromoethane to form a compound of formula (VII) and 
reakcija spoja formule (VI) sa 1,2-dibrometanom čime nastaje spoj formule (VII), te [image]
the glutamic acid residue, corresponding to the position 570 in the sequence of the native CyaA of Bordetella pertussis as defined in SEQ ID NO: 1, is substituted by a glutamine residue; and 
(1) zamjeni ostatka glutaminske kiseline, koji odgovara položaju 570 u sekvenci nativnog CyaA u Bordetella pertussis kako je definirano u SEQ ID NO:1, glutaminom;
The composition according to claim 1, wherein the composition is in the form of a tablet. 
Preparat sukladno patentnom zahtjevu 2 ili 3, naznačen time, što je preparat u obliku oralne tablete.